Tag
Continuous ocrelizumab treatment over 10 years in relapsing MS significantly delays disability progression, reduces relapse rates, and maintains a favorable safety profile, underscoring the clinical benefit of early high-efficacy therapy.
The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad th
Cascade genetic screening in hereditary transthyretin amyloidosis (ATTRv) enables earlier diagnosis and intervention, improving survival and highlighting the need for variant-specific surveillance strategies.
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.
